rs11079788 — TBX21 TBX21 Regulatory Variant

TBX21 Intron Variant — The Th1 Regulator and Your Atopic Risk

T-bet¹¹ T-bet
T-bet (T-box expressed in T cells) is the master transcription factor that drives naive CD4+ T cells toward Th1 differentiation and simultaneously represses Th2 commitment. It is encoded by TBX21 on chromosome 17q21.32 is one of the most important switches in adaptive immunity. When T-bet is expressed robustly, the immune system generates IFN-γ-producing Th1 responses calibrated for intracellular pathogens. When T-bet activity is reduced — whether by disease, environment, or genetics — the Th2 program gains ground, favouring IL-4, IL-5, and IL-13 production, IgE class-switching, eosinophil recruitment, and the constellation of responses that underlie atopic dermatitis, allergic rhinitis, and asthma. rs11079788 sits in intron 3 of TBX21 (GRCh38 chr17:47,743,357, c.768+165C>T), a region likely involved in regulating TBX21 splicing or expression. It is one of multiple variants in the TBX21 gene linked to allergic disease risk.

The Mechanism

rs11079788 is an intronic variant that does not alter the T-bet protein sequence. Its influence is regulatory: intronic variants can affect alternative splicing²² alternative splicing
variations in pre-mRNA processing that change which exons are included in the final transcript, altering protein isoform ratios or total expression levels, create or destroy branch-point sequences, or modulate local chromatin accessibility. The T allele at rs11079788 is associated with higher baseline frequencies of CD4+CD25+ regulatory T cells (Tregs) in neonatal cord blood — TT homozygotes showed 2.79% CD4+CD25+ cells versus 1.78% in CC homozygotes (p<0.05), a 57% relative increase in Treg markers at birth. This elevated Treg frequency may dampen Th2 overactivation early in life, shifting the immune set-point toward tolerance and reducing atopic sensitization. The functional promoter context of TBX21 is well-established: the [related promoter variant rs4794067 (-1993T>C) | Akahoshi et al. Hum Genet 2005; increases nuclear protein binding affinity and TBX21 transcriptional activity; OR 1.93 for aspirin-induced asthma with the C allele](https://pubmed.ncbi.nlm.nih.gov/15806396/³³ https://pubmed.ncbi.nlm.nih.gov/15806396/) shows that small changes in TBX21 regulatory elements have measurable downstream consequences on allergy susceptibility.

The Evidence

The most direct evidence for rs11079788 comes from a birth cohort study of 200 German neonates⁴⁴ birth cohort study of 200 German neonates
Casaca et al. PLoS One 2012; cord blood mononuclear cells genotyped for TBX21 and HLX1 polymorphisms; children followed to age 3. Homozygous TT carriers had significantly fewer symptoms of atopic dermatitis at age 3 (19%) compared to heterozygous CT carriers (23%) and CC homozygotes (36%), a dose-response gradient with p=0.03. No differences in cytokine secretion were detected, pointing to Treg-mediated rather than direct cytokine-mediated protection.

Broader TBX21 haplotype work is consistent with this direction. A Norwegian childhood asthma study of 948 children⁵⁵ Norwegian childhood asthma study of 948 children
Munthe-Kaas et al. J Allergy Clin Immunol 2008 found that a TBX21 haplotype including rs11650354 and rs16947078 conferred OR 8.3 for allergic asthma in homozygotes. A large cross-sectional German study of 3,099 children⁶⁶ large cross-sectional German study of 3,099 children
Suttner et al. JACI 2009 identified 43 TBX21 polymorphisms with three tagging SNPs significantly increasing childhood asthma risk (ORs 1.39–2.60), and showed that TBX21 variants interact with HLX1 variants to increase asthma risk more than 3-fold in combination. These converging lines of evidence establish TBX21 as a genuine childhood allergy susceptibility gene, with rs11079788 representing a variant whose T allele associates with a protective immune phenotype — elevated Treg markers and less early atopic disease — that is independent of direct cytokine secretion effects.

Practical Implications

CC homozygotes, who lack the protective T allele, show the lowest neonatal Treg frequency and the highest observed rates of atopic dermatitis in the first three years of life. This does not mean atopic disease is inevitable — environment, microbiome, and other genetic factors all contribute — but it identifies a Th1/Treg-axis susceptibility that can inform early preventive choices. Strategies that support Th1 immune development and Treg induction in early life have the strongest evidence: probiotic exposure, diverse environmental microbiome contact, and avoidance of Th2-skewing early antibiotic use. For adults with active allergic disease, the TBX21 genetic context supports targeting the Th2-inflammatory axis specifically rather than non-selective immune suppression.

Interactions

rs11079788 sits within the broader TBX21 haplotype block that includes rs4794067 (promoter -1993T>C), rs2240017 (H33Q coding variant), rs16947078, rs11650354, and rs9910408. These variants are in partial linkage disequilibrium and collectively influence TBX21 expression level and IFN-γ output. Carriers of rs11079788-C (common allele) who also carry risk alleles at rs4794067 or rs16947078 may have compound Th2 susceptibility via independent regulatory mechanisms at the same gene locus.

HLX1 (the Th1 homeobox co-transcription factor) variants interact with TBX21 variants to increase childhood asthma risk more than 3-fold in combination. Carriers of rs11079788-C should be aware that HLX1 variant status modulates their effective Th1 capacity independently of TBX21 alone.